# PEP-Therapy

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pep-therapy

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.pep-therapy.com
- Total disclosed funding: $4M
- Latest round: Series A (May 19, 2021)
- Investors on record: 5

## About

Based in France, PEP-Therapy develops targeted peptide-based therapies specifically designed for cancer treatment, including pancreatic cancer and ovarian adenocarcinoma.Founded in 2014 and headquartered in Paris, France, PEP-Therapy focuses on developing innovative cancer therapies. The company has successfully completed 5 deals, with its most recent funding round on July 22, 2021, raising EUR 1.573 mn in a Series A led by Eurazeo PME, along with participation from Business Angels Des Grandes Ecoles and i&i Prague. CEO Antoine PRESTAT has been at the helm since its inception.PEP-Therapy specializes in the development of innovative peptide-based therapies aimed at targeting various forms of cancer, particularly pancreatic cancer and ovarian adenocarcinoma. Their lead product, PEP-010, has received FDA Orphan Drug Designation for the treatment of pancreatic cancer. PEP-010 functions by inducing apoptosis in cancer cells, which can be monitored through pharmacodynamic biomarkers, providing a measurable response to treatment. The company has also demonstrated PEP-010's efficacy as a monotherapy and in combination with paclitaxel for resistant forms of ovarian adenocarcinoma. PEP-Therapy markets its products primarily within the United States and Europe, targeting healthcare providers and research institutions involved in cancer treatment and clinical research.In the most recent year reported, PEP-Therapy generated revenue of EUR 1,476.4 mn, with a reported EBITDA of EUR -990,890 in 2020. The company’s revenue model involves partnerships, collaborations, and direct sales of their flagship product, PEP-010, as well as potential collaborations for clinical trials and development agreements.Following the Series A funding of EUR 1.573 mn raised on July 22, 2021, PEP-Therapy plans to utilize these funds to finance the Phase I a/b clinical trial of PEP-010 for the treatment of advanced solid tumors. The company aims to expand its product offerings and may look to enter new markets as it progresses with its clinical trials and development initiatives.

## Funding rounds

- Series A, May 19, 2021, $2.6M — Seventure Partners, Italian Angels for Growth, Business Angels Des Grandes Ecoles, Magna Capital Partners, Doorway Capital
- Seed, Apr 21, 2015, $1.4M — Seventure Partners

## Investors

- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Seed, Series A
- Italian Angels for Growth (https://capitalatlas.ai/funds/italian-angels-for-growth) — Series A
- Business Angels Des Grandes Ecoles — Series A
- Magna Capital Partners (https://capitalatlas.ai/funds/magna-capital-partners) — Series A
- Doorway Capital (https://capitalatlas.ai/funds/doorway-capital) — Series A